0000950170-24-030309.txt : 20240312 0000950170-24-030309.hdr.sgml : 20240312 20240312200129 ACCESSION NUMBER: 0000950170-24-030309 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240309 FILED AS OF DATE: 20240312 DATE AS OF CHANGE: 20240312 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brady Todd C CENTRAL INDEX KEY: 0001579179 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36332 FILM NUMBER: 24744153 MAIL ADDRESS: STREET 1: C/O EVOKE PHARMA, INC. STREET 2: 505 LOMAS SANTA FE DRIVE CITY: SOLANA BEACH STATE: CA ZIP: 92075 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001341235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-761-4904 MAIL ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: Aldexa Therapeutics, Inc. DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Neuron Systems Inc DATE OF NAME CHANGE: 20051012 4 1 ownership.xml 4 X0508 4 2024-03-09 0001341235 Aldeyra Therapeutics, Inc. ALDX 0001579179 Brady Todd C C/O ALDEYRA THERAPEUTICS, INC. 131 HARTWELL AVENUE LEXINGTON MA 02421 true true false false President and CEO false Common Stock 2024-03-11 4 S false 97914 3.2735 D 1556622 D Common Stock 2024-03-12 4 S false 85324 3.05 D 1471298 D Stock Option (right to buy) 3.62 2024-03-09 4 A false 1081201 0.00 A 2034-03-08 Common Stock 1081201 1081201 D These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.35. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.11. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2024. /s/ Todd C. Brady 2024-03-12